Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2...

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive...

Prof Hope Rugo - University of California, San Francisco, USA

SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies ( Prof Hope Rugo - University of California, San Francisco, USA )

Preliminary results of earlier steroid use with axicabtagene ciloleucel in...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Preliminary results of earlier steroid use with axicabtagene ciloleucel in patients with R/R large B cell lymphoma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE)...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

POLO Trial: Olaparib as a maintenance treatment following first-line...

Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona...

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ( Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )

Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in...

Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas ( Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA )

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

More from ecancer